Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

被引：1

作者：

Spigel, David ^{[1
]}

Pietanza, M. Catherine ^{[2
]}

Bauer, Todd ^{[1
]}

Ready, Neal ^{[3
]}

Morgensztern, Daniel ^{[4
]}

Glisson, Bonnie S. ^{[5
]}

Byers, Lauren Averett ^{[5
]}

Johnson, Melissa ^{[1
]}

Burris, Howard ^{[1
]}

Robert, Francisco ^{[6
]}

Han, Tae ^{[7
]}

Bheddah, Sheila ^{[7
]}

Theiss, Noah ^{[8
]}

Watson, Sky ^{[8
]}

Mathur, Deepan ^{[8
]}

Vennapusa, Bharathi ^{[8
]}

Strickland, Donald ^{[1
]}

Zayed, Hany ^{[7
]}

Dylla, Scott ^{[7
]}

Peng, Stanford ^{[7
]}

Govindan, Ramaswamy ^{[4
]}

Rudin, Charles ^{[9
]}

机构：

[1] Tennessee Oncol PLCC, Sarah Cannon Res Inst, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] Abbvie Stemcentrx Llc, San Francisco, CA USA

[8] Roche Diagnost, Tucson, AZ USA

[9] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

clinical trial; Rovalpituzumab tesirine; Delta-like protein 3; SCLC;

D O I：

10.1016/j.jtho.2016.11.252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA05.03

引用

页码：S260 / S261

页数：2

共 48 条

[31] CLINICAL PHARMACOLOGY CHARACTERIZATION OF AMG 119, A CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY TARGETING DELTA-LIKE LIGAND 3 (DLL3), IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
Zhou, D.
Byers, L.
Sable, B.
Smit, M.
Sadraei, N. Hashemi
Dutta, S.
Upreti, V.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S61 - S61
[32] Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Morgensztern, Daniel
Besse, Benjamin
Greillier, Laurent
Santana-Davila, Rafael
Ready, Neal
Hann, Christine L.
Glisson, Bonnie S.
Farago, Anna F.
Dowlati, Afshin
Rudin, Charles M.
Le Moulec, Sylvestre
Lally, Satwant
Yalamanchili, Sreeni
Wolf, Juergen
Govindan, Ramaswamy
Carbone, David P.
CLINICAL CANCER RESEARCH, 2019, 25 (23) : 6958 - 6966
[33] Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.
Navarro, Alejandro
Aix, Santiago Ponce
Barneto-Aranda, Isidoro C.
Smit, Egbert F.
Lopez-Vilarino, Jose Antonio
Nieto, Antonio
Kahatt, Carmen Maria
Zeaiter, Ali Hassan
Cousin, Sophie
Bischoff, Helge
Roubec, Jaromir
Syrigos, Konstantinos
Paz-Ares, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
Bylsma, Lauren C.
Pundole, Xerxes
Ju, Chia-Hsin
Hooda, Naushin
Movva, Naimisha
Elkhouly, Ehab
Bebb, Gwyn
Fryzek, Jon
Martinez, Pablo
Balasubramanian, Akhila
Dingemans, Anne-Marie C.
TARGETED ONCOLOGY, 2023, 18 (06) : 821 - 835
[35] Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
Lauren C. Bylsma
Xerxes Pundole
Chia-Hsin Ju
Naushin Hooda
Naimisha Movva
Ehab Elkhouly
Gwyn Bebb
Jon Fryzek
Pablo Martinez
Akhila Balasubramanian
Anne-Marie C. Dingemans
Targeted Oncology, 2023, 18 : 821 - 835
[36] Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
Smit, Marie-Anne Damiette
Borghaei, Hossein
Owonikoko, Taofeek Kunle
Hummel, Horst-Dieter
Johnson, Melissa Lynne
Champiat, Stephane
Salgia, Ravi
Udagawa, Hibiki
Boyer, Michael J.
Govindan, Ramaswamy
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[37] Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
Minocha, Mukul
Thompson, Corbin G.
Murphy, Alexis
Zhou, Yanchen
Brandl, Christian
Parkes, Amanda
Chen, Xi
Yu, Brian
Martinez, Pablo
Houk, Brett E.
CLINICAL PHARMACOKINETICS, 2024, 63 (12) : 1757 - 1768
[38] Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer
Masayuki Shirasawa
Tatsuya Yoshida
Kouya Shiraishi
Naoko Goto
Shigehiro Yagishita
Tatsuya Imabayashi
Yuji Matsumoto
Ken Masuda
Yuki Shinno
Yusuke Okuma
Yasushi Goto
Hidehito Horinouchi
Masaya Yotsukura
Yukihiro Yoshida
Kazuo Nakagawa
Katsuhiko Naoki
Takaaki Tsuchida
Ryuji Hamamoto
Noboru Yamamoto
Noriko Motoi
Takashi Kohno
Shun-ichi Watanabe
Yuichiro Ohe
British Journal of Cancer, 2023, 129 : 2003 - 2013
[39] Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132) in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).
Starodub, Alexander
Camidge, D. Ross
Scheff, Ronald J.
Thomas, Sajeve Samuel
Guarino, Michael J.
Masters, Gregory A.
Kalinsky, Kevin
Gandhi, Leena
Bardia, Aditya
Messersmith, Wells A.
Ocean, Allyson J.
Maliakal, Pius P.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
Heist, Rebecca Suk
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer
Shirasawa, Masayuki
Yoshida, Tatsuya
Shiraishi, Kouya
Goto, Naoko
Yagishita, Shigehiro
Imabayashi, Tatsuya
Matsumoto, Yuji
Masuda, Ken
Shinno, Yuki
Okuma, Yusuke
Goto, Yasushi
Horinouchi, Hidehito
Yotsukura, Masaya
Yoshida, Yukihiro
Nakagawa, Kazuo
Naoki, Katsuhiko
Tsuchida, Takaaki
Hamamoto, Ryuji
Yamamoto, Noboru
Motoi, Noriko
Kohno, Takashi
Watanabe, Shun-ichi
Ohe, Yuichiro
BRITISH JOURNAL OF CANCER, 2023, 129 (12) : 2003 - 2013

← 1 2 3 4 5 →